| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10070479 | European Journal of Surgical Oncology (EJSO) | 2005 | 9 Pages |
Abstract
Provided doses at 1Â mg or higher are used, TM-ILP with TNF dose reduction for both melanoma and non-melanoma patients seems to be as effective as the standard dose procedure in terms of response rate and patient outcome. Numbers to formally confirm or reject this hypothesis are too large for such a non-inferiority trial to be conducted in patients with these rare conditions.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.J. Grünhagen, J.H.W. de Wilt, A.N. van Geel, W.J. Graveland, C. Verhoef, A.M.M. Eggermont,